^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    QBS72S

    i
    Other names: QBS72S, QBS10072S, QBS-72S, QBS'72S, NBQ72S
    Associations

    News

    Trials
    Company:
    Quadriga Biosci
    Drug class:
    Alkylating agent
    Related drugs:
    Associations

    News

    Trials
    1m
    INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) (clinicaltrials.gov)
    P2, N=460, Recruiting, Patrick Wen, MD | Trial completion date: Apr 2027 --> Apr 2028 | Trial primary completion date: Feb 2027 --> Feb 2028
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 R132
    |
    temozolomide • Nerlynx (neratinib) • Verzenio (abemaciclib) • CC-115 • QBS72S
    2ms
    Study Assessing QBS72S For Treating Brain Metastases (clinicaltrials.gov)
    P2, N=21, Active, not recruiting, Stanford University | Recruiting --> Active, not recruiting | N=35 --> 21 | Trial completion date: Aug 2026 --> Nov 2025
    Enrollment closed • Enrollment change • Trial completion date
    |
    QBS72S
    1year
    INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) (clinicaltrials.gov)
    P2, N=460, Recruiting, Patrick Wen, MD | Trial completion date: Dec 2025 --> Apr 2027 | Trial primary completion date: Mar 2025 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 R132H • IDH1 R132
    |
    temozolomide • Nerlynx (neratinib) • QBS72S
    over1year
    INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) (clinicaltrials.gov)
    P2, N=460, Recruiting, Patrick Wen, MD | N=250 --> 460
    Enrollment change
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    temozolomide • Nerlynx (neratinib) • QBS72S
    almost2years
    Study Assessing QBS72S For Treating Brain Metastases (clinicaltrials.gov)
    P2, N=40, Recruiting, Melanie Hayden Gephart | Phase classification: P2a --> P2
    Phase classification
    |
    QBS72S
    almost2years
    Successful anti-tumor effects with two novel bifunctional chemotherapeutic compounds that combine a LAT1 substrate with cytotoxic moieties in aggressive T-cell lymphomas. (PubMed, Leuk Res Rep)
    The findings demonstrated decreased survival of T-cell lymphoma lines with both compounds. Overall, the results demonstrate that LAT1 is a valuable biomarker for aggressive T-cell lymphoma counterparts and QBS10072S and QBS10096S are successful therapeutic options for these aggressive diseases.
    Journal
    |
    SLC7A5 (Solute Carrier Family 7 Member 5)
    |
    QBS72S
    over2years
    INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) (clinicaltrials.gov)
    P2, N=250, Recruiting, Patrick Wen, MD | Trial primary completion date: Dec 2024 --> Mar 2025
    Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 R132H • IDH1 R132
    |
    temozolomide • Nerlynx (neratinib) • QBS72S
    over2years
    INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) (clinicaltrials.gov)
    P2, N=250, Recruiting, Patrick Wen, MD | Active, not recruiting --> Recruiting | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
    Enrollment open • Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 R132H • IDH1 R132
    |
    temozolomide • Nerlynx (neratinib) • QBS72S
    3years
    Study Assessing QBS72S For Treating Brain Metastases of Triple Negative Breast Cancer (clinicaltrials.gov)
    P2a, N=35, Recruiting, Melanie Hayden Gephart | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • PGR expression
    |
    QBS72S
    over3years
    Study Assessing QBS72S For Treating Brain Metastases of Triple Negative Breast Cancer (clinicaltrials.gov)
    P2a, N=35, Not yet recruiting, Melanie Hayden Gephart | Initiation date: Apr 2022 --> Jul 2022
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • PGR expression
    |
    QBS72S
    over3years
    Study Assessing QBS72S For Treating Brain Metastases of Triple Negative Breast Cancer (clinicaltrials.gov)
    P2a, N=35, Not yet recruiting, Melanie Hayden Gephart
    New P2a trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • PGR expression
    |
    QBS72S
    almost4years
    INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) (clinicaltrials.gov)
    P2, N=250, Active, not recruiting, Patrick Y. Wen, MD | Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2021 --> Dec 2023
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 R132H • IDH1 R132
    |
    temozolomide • Nerlynx (neratinib) • QBS72S